3SBio and Verseau Therapeutics have formed a partnership to develop and commercialize novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers. Verseau’s proprietary drug discovery platform generates first-in-class macrophage checkpoint modulators (MCMs) to benefit patients with cancer, immune and inflammatory diseases.   Under the terms of the agreement, 3SBio will receive an exclusive license to develop and commercialize a select number of MCM antibodies f...